<DOC>
	<DOCNO>NCT01652937</DOCNO>
	<brief_summary>Phase II study design evaluate safety efficacy BIIB057 Subjects Rheumatoid Arthritis experience Inadequate Response Disease-Modifying Antirheumatic Drugs ( DMARDs ) .</brief_summary>
	<brief_title>BIIB057 Subjects With Rheumatoid Arthritis Inadequate Response Disease-Modifying Antirheumatic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult onset RA satisfy 2010 Revised ACR Criteria Classification RA disease history least 6 month Active RA define : least 4 swollen joint ( base 28joint count ) , least 4 tender joint ( base 28joint count ) , highsensitivity CRP ( hsCRP ) 10mg/L great No prior treatment biologics Receiving DMARD therapy least 3 month , use regimen stable least 28 day prior screen History inflammatory joint disease RA Abnormal chest Xray consistent tuberculosis , malignancy , infection History malignancy , carcinoma situ , highgrade dysplasia History opportunistic infection , infection require treatment , serious local infection , recent fever , active herpes zoster EpsteinBarr virus , diagnosis family history CreutzfeldtJakob disease . Clinically significant cardiac disease Treatment prednisone &gt; 10 mg orally daily Intraarticular steroid injection within 28 day screen Clinically significant abnormality hematology blood chemistry value screen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>DMARD-IR</keyword>
</DOC>